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ABSTRACT
Objective Women with severe aortic valve stenosis
(AS) have better LV systolic function and more concentric
LV geometry than their male counterparts. However, sex
differences in cardiovascular (CV) outcome during
progression of AS have not been reported from a
longitudinal prospective study.
Methods Doppler echocardiography and CV events
were recorded during a median of 4.0 years in 979 men
and 632 women aged 28–86 (mean 67±10) years in
the Simvastatin Ezetimibe in Aortic Stenosis (SEAS)
study. LV systolic function was assessed by EF and
midwall shortening (MWS). Study outcomes were AS-
related events, ischaemic CV events and total mortality.
Results The annular cumulative incidence of AS events,
ischaemic CV events and death was 8.1%, 3.4% and
2.8% in women, and 8.9%, 4.4% and 2.4% in men,
respectively. Women and men had similar AS progression
rate whether measured by peak jet velocity, mean
gradient or valve area. In multivariate analyses, female
sex independently predicted less reduction in LV MWS
and EF during follow-up (both p<0.05). In time-varying
Cox analyses, women had a 40% lower rate of
ischaemic CV events (95% CI 21% to 54%), in
particular, more than 50% lower rate of stroke and
coronary artery bypass grafting, and a 31% lower all-
cause mortality (95% CI 1% to 51%), independent of
active study treatment, age and hypertension, as well as
time-varying valve area, low systolic function and
abnormal LV geometry. AS event rate did not differ by
sex.
Conclusions In the SEAS study, women and men had
similar rates of AS progression and AS-related events.
However, women had lower total mortality and
ischaemic CV event rate than men independent of
confounders.
Trial registration number ClinicalTrials.gov
identifier: NCT00092677.
Aortic valve stenosis (AS) is present in 2%–7% of
the population above 65 years of age and is the
most common type of valvular heart disease requir-
ing open heart surgery in developed countries.1 2
Management of AS is based upon assessment of
clinical cardinal symptoms and of AS severity.3
Echocardiography is the key technique to assess AS
severity and structural and functional consequences
for the LV.4
Previous cross-sectional studies in patients with
severe, symptomatic AS have found that women
present better LV systolic function than men, and
more concentric LV geometry.5–8 Recently, women
were found to have lower aortic valve calcium
score by Agatston units on multislice CT than men
for the same severity of AS.9 Furthermore, sex dif-
ferences in comorbidities like hypertension, renal
dysfunction and coronary artery disease are well
known in patients with AS.10–12 However, although
sex differences in comorbidities as well as in the
pathophysiology of AS both at the aortic valve and
LV level have been described, it is not clear
whether women and men with AS have different
progression rates or prognosis.13
The present, prospectively planned analysis
aimed to compare AS progression rate and cardio-
vascular (CV) outcome between women and men
during progression of AS.
METHODS
Study population
The Simvastatin Ezetimibe in Aortic Stenosis
(SEAS) study was a randomised, double-blind,
placebo-controlled study which assessed the effect
of combined treatment with simvastatin and ezeti-
mibe on AS progression and CV morbidity and
mortality in 1873 patients with initially asymptom-
atic, mild-moderate AS.14 Patients with known cor-
onary artery disease, peripheral arterial disease,
cerebrovascular disease, diabetes mellitus or any
condition requiring lipid-lowering therapy were
excluded from the SEAS study. The present pro-
spectively planned analysis included the 1611
patients in whom LV geometry could be assessed
on the echocardiogram both at baseline and at least
one additional visit before occurrence of any major
study outcome.
Hypertension was defined as history of hyperten-
sion, use of antihypertensive treatment reported by
the attending physician or blood pressure ≥140/
90 mm Hg at the baseline clinical visit.12 Blood
tests, including measures of serum total and low-
density lipoprotein (LDL)-cholesterol and assess-
ment of kidney function by serum creatinine, were
analysed at the SEAS core laboratory, PPD Global
Central Labs (Zaventum, Belgium).
Echocardiographic measurements
Echocardiography was performed at baseline and
then annually and before valve surgery at the 173
SEAS participating centres following a standardised
performance protocol.10 12 The last study visit was
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defined as the last echocardiogram performed before a CV event
in patients who experienced study endpoints or as the final
study echocardiogram in those without events. All echocardio-
graphic analyses were performed at the SEAS Echocardiography
Core Laboratory at Haukeland University Hospital, Bergen,
Norway,10 12 following current guidelines.4 11
Assessment of AS severity
Severity of AS was evaluated by peak aortic jet velocity, mean
transvalvular gradient, aortic valve area and aortic valve area
indexed for body surface area, as well as pressure recovery
adjusted aortic valve area index, i.e. the energy loss index
(ELI).4 15
Assessment of LV geometry
LV mass was calculated by the Devereux equation,11 and LV
hypertrophy was considered present if LV mass/height2.7
≥46.7 g/m2.7 in women and 49.2 g/m2.7 in men.16 Concentric
geometry was considered present if relative wall thickness
≥0.43.11 Abnormal LV geometry was considered present if either
LV hypertrophy or increased relative wall thickness was found.
Assessment of LV systolic function
LVEF was measured by the Simpson’s biplane method.11
Gender-specific cut-off values for identification of low LV sys-
tolic function were used for EF and midwall shortening
(MWS).17 EF was considered low if <51% in men and <55%
in women.17 MWS was calculated using validated equations and
considered low if <14% in men and <16% in women.17
Study outcomes
The primary endpoint in the SEAS study was major CV events
(combined AS-related events and ischaemic CV events).14
AS-related events included combined aortic valve replacement,
hospitalisation for congestive heart failure due to AS or death
from CV causes. Ischaemic CV events included combined non-
fatal myocardial infarction, hospitalisation for unstable angina,
coronary revascularisation at the time of aortic valve replace-
ment, non-hemorrhagic stroke and CV death. The present ana-
lysis also assessed all-cause mortality, a tertiary study endpoint.
All study endpoints were adjudicated by an independent classifi-
cation committee.
Statistical analyses
Comparisons between women and men were done by χ2 test,
unpaired Student’s t test, full-factorial two-way analysis of vari-
ance (ANOVA) with Sidak’s posthoc test or ANOVA for
repeated measures, as appropriate. Independent covariates of
reduction in EF and MWS from baseline to the last study visit
were identified in multivariate linear regression analyses, run
with an enter procedure and collinearity diagnostics. The
impact of sex on rate of AS-related and ischaemic CV events and
on total mortality was tested in univariate and multivariate time-
varying Cox proportional hazard analyses including age, hyper-
tension and active study treatment, as well as AS severity by
ELI, presence of low EF and low MWS, and abnormal LV geom-
etry as time-varying covariates. Results are presented as HRs
with 95% CI, as well as plots of survival free of ischaemic CV
events and overall survival in women and men with adjustment
for the mean values of the other covariates included in the
multivariate Cox models. Two-tailed p≤0.05 was considered sig-
nificant both in univariate and multivariate analyses.
RESULTS
Progression of AS
Women were older (69±9 vs. 66±10 years), included more
patients with hypertension (91% vs. 83%) and had better renal
function than men (all p<0.001, table 1). Sixteen per cent of
Table 1 Clinical and echocardiographical characteristics of women and men at baseline and at the last study visit
Women (632) Men (979)
Baseline Last visit Baseline Last visit
Body mass index (kg/m2) 26.8±5.1‡ 26.4±5.5 26.8±3.7§ 26.7±4.0
Systolic blood pressure (mm Hg) 146±20†‡ 142±19* 144±20§ 138±18
Diastolic blood pressure (mm Hg) 82±10‡ 78±10 82±10§ 79±10
Heart rate (beats/min) 68±11* 69±12* 64±11§ 66±13
Total cholesterol (mmol/L) 6.0±1.0*‡ 4.9±1.4* 5.5±0.9§ 4.4±1.3
LDL cholesterol (mmol/L) 3.7±0.9*‡ 2.6±1.3* 3.5±0.9§ 2.4±1.2
Creatinine (mmol/L) 84±13*‡ 77±17* 99±15§ 93±21
Serum glucose (mmol/L) 5.20±0.72*‡ 5.35±0.74*§ 5.34±0.84 5.54±1.09
Peak aortic jet velocity (m/s) 3.07±0.53‡ 3.74±0.78 3.10±0.55§ 3.67±0.76
Mean transvalvular gradient (mm Hg) 23±9‡ 35±15† 23±9§ 33±14
Aortic valve area (cm2) 1.12±0.37*‡ 0.98±0.36* 1.38±0.50§ 1.24±0.48
Aortic valve area index (cm2/m2) 0.64±0.21*‡ 0.57±0.21* 0.69±0.25§ 0.63±0.24
ELI (cm2/m2) 0.86±0.40†‡ 0.66±0.29* 0.92±0.47§ 0.73±0.33
EF (%) 67±6‡ 65±6* 66±7§ 64±7
MWS (%) 17.4±3.3*‡ 14.1±2.9† 16.9±3.3§ 13.8±2.8
LV mass index (g/m2.7) 43±14*‡ 51±15* 47±15§ 55±17
Relative wall thickness 0.35±0.09‡ 0.48±0.12 0.36±0.09§ 0.47±0.12
Mitral regurgitation (mild/moderate) 54%† 57%† 45%§ 50%
Aortic regurgitation (mild/moderate) 56%†‡ 64%† 63%§ 71%
Data are mean±SD.
*p<0.001 and †p<0.05 between women and men at either baseline or last visit; ‡p<0.001 in women for comparison between values at baseline and at last visit; §p<0.01 in men for
comparison between values at baseline and at last visit.
ELI, energy loss index; MWS, midwall shortening; LDL, low-density lipoprotein.
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women were smokers at study baseline vs. 21% of men (p<0.05).
Women also had smaller aortic valve area both at inclusion and at
the last study visit, also when adjusted for pressure recovery in the
aortic root, indicating more severe AS (table 1 and figure 1).
Mild–moderate mitral regurgitation was more prevalent in
women and mild–moderate aortic regurgitation more prevalent
in men (both p<0.05) (table 1). No patient had severe mitral or
aortic valve regurgitation, reflecting the exclusion criteria in the
SEAS study.
Although there was no stratification by sex in the randomisa-
tion procedure, randomisation to active study treatment did not
differ between sexes: 50% of women on active treatment vs.
51% of men (p=0.61).
During a median of 4 years follow-up, AS progression rate
did not differ between women and men, whether assessed from
peak aortic jet velocity, mean transvalvular gradient, aortic valve
area, aortic valve area index or ELI (table 2).
Low EF was uncommon in this population, reflecting the
exclusion criteria used in the SEAS study. New-onset low EF was
equally common in women and men during follow-up (figure 2).
However, the absolute reduction in EF from baseline to the last
examination was significantly larger in men (2.6% vs. 1.4%,
p<0.01) (table 1). Despite the low prevalence of reduced EF, low
MWS was commonly found (p<0.001 at all visits, figure 2).
In multivariate regression analyses, male sex independently
predicted larger reduction both in EF and MWS during progres-
sion of AS (table 3). Baseline kidney function assessed by the
serum creatinine level did not significantly influence reduction
in EF or MWS in similar regression models.
CV outcome
During follow-up (median 4.0 years, IQR 3.0–4.2 years), a total
of 554 major CV events occurred, among them 517 AS-related
events and 260 ischaemic CV events. The ischaemic events
included 56 strokes, 142 deaths from any cause (71 from CV
causes), 28 non-fatal myocardial infarctions, 11 hospitalisations
for unstable angina, 20 percutaneous coronary interventions
and 142 coronary artery bypass revascularisations. Women had
significantly lower risk of major CV events and ischaemic CV
events (figure 3), also after adjustment for active study treat-
ment, age and hypertension and time-varying ELI, low EF, low
MWS and abnormal LV geometry in time-varying multivariate
Cox analyses (table 4). Neither higher total cholesterol at base-
line nor LDL cholesterol was associated with higher rate of
Figure 1 Progression of aortic valve stenosis in women and men assessed by 4 key variables: peak aortic jet velocity, mean pressure gradient,
aortic valve area and energy loss index (ELI), at 4 different study visits: baseline, 1-year visit, 2-year visit and final visit. *p<0.05 for comparison
between women and men at each visit.








Peak aortic jet velocity (m/s/year) 0.21±0.26 0.19±0.31 0.13
Mean transvalvular gradient (mm Hg/
year)
4±5 4±6 0.15
Aortic valve area (cm2/year) 0.04±0.14 0.03±0.32 0.77
Aortic valve area index (cm2/m2/year) 0.02±0.08 0.02±0.16 0.63
ELI (cm2/m2/year) 0.06±0.13 0.05±0.23 0.52
ELI, energy loss index.
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ischaemic CV events when added to the time-varying Cox
model run in the whole study population as well as separately in
women and men. When current smoking at baseline was added
to these models, the results remained unchanged. Analysing the
association between sex and specific types of ischaemic CV
events using similar Cox models, female sex predicted more
than 50% lower rate of both stroke and coronary artery disease
requiring concomitant bypass grafting at the time of aortic valve
replacement (table 4). Women also had a 31% lower all-cause
mortality rate independent of covariates (table 4 and figure 4).
The annular incidence of ischaemic CV events was 3.4% in
women and 4.4% in men (p<0.007).
DISCUSSION
The present large, prospective, longitudinal study is the first to
report on AS progression and associated CV events using a sex-
specific approach. In particular, women and men had similar AS
progression rates. However, women had lower total mortality
despite more severe AS by echocardiographic indices and also
lower rate of ischaemic CV events during a median of 4 years
follow-up. The present study extends previous knowledge on
sex differences from cross-sectional studies in AS which have
demonstrated pathophysiological differences between women
and men both at the aortic valve and LV level, including less
valve calcification, more concentric LV geometry and extracellu-
lar myocardial fibrosis and higher indices of LV systolic function
in women.5–7 9 18–20
Progression of AS in women and men
Few studies have compared AS progression in women and men.
The Cardiovascular Health Study including echocardiographic
follow-up over a mean of 5 years in 5621 subjects ≥65 years of
age reported that 9% of subjects with aortic valve sclerosis at
the initial examination had progressed to AS on the follow-up
Figure 2 Prevalence of low midwall shortening (MWS) (continuous
line) and low EF (stippled line) in women and men at different study
visits. Mean values are adjusted for repeated measurements over time
using full-factorial analysis of variance. p Value of significance for
comparison between women and men at each visit.
Table 3 Predictors of reduction in LVEF (multiple R2=0.39,
p<0.001) and MWS (multiple R2=0.51, p<0.001) from baseline to
the last study visit
Reduction in EF Reduction in MWS
Independent variables ß p Value ß p Value
Male sex 0.13 <0.001 0.05 0.02
Age (years) 0.02 0.42 0.09 <0.001
Heart rate (bpm) 0.08 0.001 0.03 0.14
Active study treatment 0.03 0.25 0.03 0.12
Reduction in ELI (cm2/m2) −0.03 0.24 0.003 0.87
Presence of aortic regurgitation 0.01 0.68 −0.01 0.81
Presence of mitral regurgitation 0.05 0.02 0.01 0.76
LV hypertrophy 0.12 <0.001 0.06 0.006
Concentric LV geometry −0.04 0.11 0.04 0.13
Baseline EF (%) 0.60 <0.001 −0.03 0.20
Baseline MWS (%) −0.03 0.37 0.76 <0.001
ELI, energy loss index; MWS, midwall shortening.
Figure 3 Survival free of ischaemic cardiovascular (CV) events in
women and men during progression of aortic valve stenosis with
adjustment for covariates (the means of age, hypertension, active study
treatment, energy loss index, low EF and midwall shortening, and
abnormal LV geometry) and p value of significance based on Cox
proportional hazard analyses.
Table 4 The association of female sex with rates of major CV
events, ischaemic CV events and death in time-varying multivariate
Cox analyses adjusting for active study treatment, age and
hypertension, as well as time-varying ELI, low EF, low MWS and
abnormal LV geometry
HR (95% CI) p Value
Major CV events 0.83 (0.69 to 0.99) 0.04
Aortic valve events 0.85 (0.70 to 1.02) 0.08
Ischaemic events 0.60 (0.46 to 0.79) <0.001
stroke 0.47 (0.26 to 0.85) 0.01
coronary artery bypass grafting 0.49 (0.34 to 0.71) <0.001
non-fatal myocardial infarction 1.15 (0.52 to 2.54) 0.724
hospitalisation for unstable angina 0.62 (0.17 to 2.20) 0.456
percutaneous coronary intervention 0.62 (0.21 to 1.82) 0.386
Death 0.69 (0.49 to 0.99) 0.04
CV, cardiovascular; ELI, energy loss index; MWS, midwall shortening.
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examination, and progression to AS was threefold more
common among men.21 By contrast, a retrospective study by
Rosenhek et al22 including 73 women and 103 men with mild–
moderate AS, found no interaction of sex with AS progression
or outcome, while AS severity and aortic valve calcification by
echocardiography were identified as independent predictors of
progression to death or aortic valve replacement. Of note, using
the more accurate Agatston score, aortic valve calcification was
recently reported to be higher in men compared with women
irrespective of AS severity.9 The present results add to these
studies by demonstrating that the rate of progression of AS was
comparable in women and men despite differences in age and
prevalence of hypertension between sexes. However, compared
with expected sex differences in incidence of CV events based
upon general Norwegian population, the observed difference in
incidence of ischaemic CV events was much less in the present
study population.23 This finding probably reflects that AS often
is part of a systemic atherosclerotic disease.24
Sex-differences in CV outcomes in AS
Sex-related differences in atherosclerosis progression, plaque
composition and prevalence of microvascular disease have been
well documented.25 Obstructive coronary artery disease and
stroke are both more prevalent among men in the general popu-
lation <75 years of age.25 Recently, superior LV hypertrophy
regression and outcome were reported in elderly women com-
pared with men undergoing transcutaneous aortic valve replace-
ment from the prospective Placement of Aortic Transcatheter
Valve (PARTNER) trial.26 The present results extend current
knowledge by demonstrating that also after adjusting for known
confounders, women had more than 50% lower rate of ischae-
mic CV events, like stroke and coronary artery bypass surgery, as
well as 31% lower total mortality during a median of 4 years
follow-up. Of note, this was observed despite more severe AS
from echocardiographic indices and higher prevalence of hyper-
tension among women, both well-known factors associated with
impaired prognosis in AS.27 28 Reduced LVEF to <50% is a
guideline indication for valve replacement in severe AS.27 As
demonstrated, men experienced more reduction in EF and more
subclinical coronary artery disease during follow-up, but low EF
was very uncommon, probably reflecting the SEAS study exclu-
sion criteria. These preoperative differences may help explain
the observed higher LVEF and enhanced hypertrophy regression
in women in previous studies after aortic valve replacement for
AS,18 19 26 as well as the recent findings of better survival in
elderly women undergoing transcatheter aortic valve replace-
ment in a retrospective sub-analysis from the PARTNER trial.26
Study limitations
This report is based on the prospective follow-up of a selected
population of patients with AS and without diabetes mellitus,
clinical manifest vascular disease, dyslipidaemia, or other signifi-
cant valvular disease participating in the SEAS study. Exclusion
of patients with diabetes mellitus was done based upon known
history of diabetes. Inclusion of some patients with subclinical
diabetes mellitus might have occurred, since HbA1c was not
measured. Extrapolation of the results to other types of patients
with AS should be done with caution. However, in patients with
AS with clustering of CV risk factors or established CV disease,
even higher incidence of ischaemic CV events is to be expected,
and active CV prevention may be even more effective.
In conclusion, the present results demonstrate that women
and men have similar rates of AS progression and AS-related
events. However, women have lower total mortality and
Figure 4 Overall survival in women and men during progression of
aortic valve stenosis with adjustment for covariates (the means of age,
hypertension, active study treatment, energy loss index, low EF and
midwall shortening, and abnormal LV geometry) and p value of
significance based on Cox proportional hazard analysis.
Key messages
What is known on this subject?
Aortic stenosis (AS) progression rate and cardiovascular (CV)
outcome during AS progression have not been reported
individually for women and men from a prospective,
longitudinal study.
What might this study add?
This study documents that AS progression rate is similar in
women and men. Women had lower rate of ischaemic CV
events and total death than men during a median of 4 years
follow-up independent of confounding factors like age,
hypertension, AS severity, LV geometry, systolic function and
lipid lowering treatment. However, the observed sex difference
in rate of ischaemic CV events was much smaller than expected
from population-based studies, with an absolute annular
incidence of 3.4% in women and 4.4% in men, respectively,
meaning only 30% lower absolute incidence in women
compared with men. It is well known that AS is associated with
systemic atherosclerosis. Of note, the most common type of
ischaemic CV event in our study was concomitant coronary
artery bypass grafting during planned surgical aortic valve
replacement. The total number of acute myocardial infarctions
was low in this population during the study period with an
absolute annular incidence of 0.5% vs. 0.4% in women and
men, respectively (not significant).
How might this impact on clinical practice?
Our findings underscore that progression of AS occurs at
comparable rates in women and men, and
guideline-recommended follow-up should be provided in both
sexes.
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ischaemic CV event rates compared with men during progres-
sion of AS, even after adjustment for confounding factors like
differences in age, prevalence of hypertension, AS severity, LV
geometry and LV systolic function.
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